Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
My Account
Do not call
En
Global Health Ltd. Share Price
Day's Range
Day's Range
Low
₹1,212.20
High
₹1,239.00
Price Summary
| Previous Close | ₹1,236.10 |
|---|---|
| Day's Range | ₹1,212.20 - ₹1,239.00 |
| Open | ₹1,226.00 |
| 52 Week Range | ₹956.00 - ₹1,456.50 |
| Volume | 88,465 |
| Market Cap | ₹0.03 |
| Previous Close | ₹1,236.85 |
|---|---|
| Day's Range | ₹1,213.00 - ₹1,238.15 |
| Open | ₹1,215.40 |
| 52 Week Range | ₹955.20 - ₹1,455.85 |
| Volume | 6,488 |
| Market Cap | ₹0.03 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | 1,093.52 |
|---|---|
| Market Cap (₹ in Mn) | 0.03 |
| Dividend Yield(%) | 0.04 |
| Price/Earning (TTM) | 59.15 |
| TTM EPS (₹) | 20.70 |
| P/E Ratio | 66.85 |
| Book Value(₹) | 8.29 |
| PAT Margin (%) | 13.04 |
| Face Value (₹) | 2.00 |
| ROCE(%) | 20.50 |
| Trade Value ( ₹ in Lacs) | 80.25 |
|---|---|
| Market Cap (₹ in Mn) | 0.03 |
| Dividend Yield(%) | 0.04 |
| Price/Earning (TTM) | 59.15 |
| TTM EPS (₹) | 20.70 |
| P/E Ratio | 66.85 |
| Book Value(₹) | 8.29 |
| PAT Margin (%) | 13.04 |
| Face Value (₹) | 2.00 |
| ROCE(%) | 20.50 |
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 8028.68 | 32041.46 |
| Expenses | N/A | N/A |
| PBT | 1258.87 | 6230.47 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 934.12 | 4615.28 |
About Global Health Ltd.
| Founded | 2004 |
|---|---|
| Managing Director | Naresh Trehan |
| NSE Symbol | MEDANTA |
Peer Comparision
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,28,785.15 | 1,793.65 | 1,548.00 - 1,548.00 |
| Divi's Laboratories Ltd. | 1,76,241.94 | 6,658.30 | 5,636.50 - 5,636.50 |
| Torrent Pharmaceuticals Ltd. | 1,51,058.35 | 4,578.20 | 3,140.10 - 3,140.10 |
| Apollo Hospitals Enterprise Ltd. | 1,22,035.07 | 8,461.00 | 6,696.50 - 6,696.50 |
| Cipla Ltd. | 1,11,179.71 | 1,382.70 | 1,165.70 - 1,165.70 |
| Zydus Lifesciences Ltd. | 1,10,474.43 | 1,104.75 | 835.50 - 835.50 |
| Dr. Reddy's Laboratories Ltd. | 1,06,149.04 | 1,275.00 | 1,148.40 - 1,148.40 |
| Lupin Ltd. | 1,02,817.88 | 2,278.35 | 1,836.80 - 1,836.80 |
| Max Healthcare Institute Ltd. | 98,307.36 | 1,012.45 | 903.00 - 903.00 |
| Mankind Pharma Ltd. | 97,952.32 | 2,380.05 | 1,909.70 - 1,909.70 |
No Records Found
Latest News
Global Health informs about updates
Anlon Healthcare informs about invitation for tv interview
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Anlon Healthcare has informed that Punitkumar Rasadia, Chairman & Managing Director of the Company, has been invited for a television interview on NDTV Profit for an exclusive discussion on ‘The Small Cap Buzzers. The television interview on NDTV Profit will be live on June 11, 2026 at 01:30 pm IST. During the interaction, the discussion primarily covered the Company's growth journey, recent developments, financial performance for FY 2025-26 and future outlook. The discussion would be based solely on publicly available information. No unpublished price sensitive information (UPSI) would be shared during the interview. Further, the interview could be cancelled, rescheduled, or postponed depending on circumstances.
AstraZeneca Pharma India informs about updates
AstraZeneca Pharma India has informed that on June 10, 2026, the company has received permission from the Central Drugs Standard Control Organization, Directorate General of Health Services, Government of India to import for sale and distribution of Trastuzumab deruxtecan 100 mg/5mL vial lyophilized powder for concentrate for solution for infusion (Brand name: Enhertu®) for an additional indication. Through this approval, Trastuzumab deruxtecan in combination with pertuzumab is indicated for the first-line treatment of adult patients with unresectable or metastatic HER2-positive (IHC3+ or ISH+) breast cancer. The receipt of this permission paves way for the marketing of Trastuzumab deruxtecan 100 mg/5mL vial lyophilized powder for concentrate for solution for infusion (Brand name: Enhertu®) in India for the specified additional indication, subject to the receipt of related statutory approvals, if any.
The above information is a part of company’s filings submitted to BSE.
Aspira Pathlab & Diagnostics informs about updates
Divis Laboratories informs about deduction of Income tax at source from payment of dividend
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Global Health Ltd. is ₹1,236.10 as of 2026-06-11.
The market capitalisation of Global Health Ltd. is ₹32,912.11 as of 2026-06-10.
The 1-year return of Global Health Ltd. is 10.60% as of 2026-06-11.
The P/E ratio of Global Health Ltd. is 66.85 as of 2026-06-11.
The 52-week high and low of Global Health Ltd. are ₹1,456.50 and ₹956.00, respectively, as of 2026-06-11.
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
